Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBIT (2016 - 2026)

Wave Life Sciences (WVE) has disclosed EBIT for 12 consecutive years, with -$31.3 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT rose 37.16% year-over-year to -$31.3 million; the TTM value through Mar 2026 reached -$196.9 million, down 56.56%, while the annual FY2025 figure was -$215.4 million, 95.09% down from the prior year.
  • EBIT hit -$31.3 million in Q1 2026 for Wave Life Sciences, up from -$56.5 million in the prior quarter.
  • Across five years, EBIT topped out at $23.0 million in Q4 2024 and bottomed at -$63.9 million in Q3 2024.
  • Average EBIT over 5 years is -$34.6 million, with a median of -$38.1 million recorded in 2022.
  • On a YoY basis, EBIT climbed as much as 222.94% in 2024 and fell as far as 1538.23% in 2024.
  • Wave Life Sciences' EBIT stood at -$43.6 million in 2022, then soared by 57.11% to -$18.7 million in 2023, then soared by 222.94% to $23.0 million in 2024, then plummeted by 345.86% to -$56.5 million in 2025, then surged by 44.57% to -$31.3 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$31.3 million, -$56.5 million, and -$56.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.